Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients.

Szudy-Szczyrek A, Mlak R, Szczyrek M, Chocholska S, Sompor J, Nogalski A, Małecka-Massalska T, Hus M.

Oncotarget. 2018 May 8;9(35):24054-24068. doi: 10.18632/oncotarget.25307. eCollection 2018 May 8.

2.

Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients.

Mlak R, Szudy-Szczyrek A, Mazurek M, Szczyrek M, Homa-Mlak I, Mielnik M, Chocholska S, Jankowska-Łęcka O, Małecka-Massalska T, Hus M.

Br J Haematol. 2019 Sep;186(5):695-705. doi: 10.1111/bjh.15972. Epub 2019 May 22.

PMID:
31115923
3.

Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.

Jung SH, Choi HJ, Shin MG, Lee SS, Hwang EC, Jung TY, Cho MS, Yang DH, Ahn JS, Kim YK, Kim HJ, Lee JJ.

Ann Hematol. 2016 Oct;95(10):1645-51. doi: 10.1007/s00277-016-2743-6. Epub 2016 Jul 1.

PMID:
27365142
4.

Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.

Butrym A, Rybka J, Łacina P, Gębura K, Frontkiewicz D, Bogunia-Kubik K, Mazur G.

Leuk Res. 2015 Dec;39(12):1462-6. doi: 10.1016/j.leukres.2015.10.007. Epub 2015 Oct 19.

PMID:
26521987
5.

Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?

Bedewy AM, El-Maghraby SM.

Eur J Haematol. 2014 Jan;92(1):13-8. doi: 10.1111/ejh.12207. Epub 2013 Oct 29.

PMID:
24118365
6.

The clinical significance of cereblon expression in multiple myeloma.

Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK.

Leuk Res. 2014 Jan;38(1):23-8. doi: 10.1016/j.leukres.2013.08.015. Epub 2013 Sep 5.

7.

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.

Huang SY, Lin CW, Lin HH, Yao M, Tang JL, Wu SJ, Chen YC, Lu HY, Hou HA, Chen CY, Chou WC, Tsay W, Chou SJ, Tien HF.

Ann Hematol. 2014 Aug;93(8):1371-80. doi: 10.1007/s00277-014-2063-7. Epub 2014 Apr 1.

8.

Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma.

Bila J, Sretenovic A, Jelicic J, Tosic N, Glumac I, Fekete MD, Antic D, Balint MT, Markovic O, Milojevic Z, Radojkovic M, Trajkovic G, Puric M, Pavlovic S, Mihaljevic B.

Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):610-615. doi: 10.1016/j.clml.2016.08.007. Epub 2016 Aug 10.

PMID:
27618360
9.

Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible.

Hungria VT, Crusoé EQ, Maiolino A, Bittencourt R, Fantl D, Maciel JF, Pessoa de Magalhaes RJ, Almeida MS, Cury P, Hisgashi F, Peres AL, Chiattone CS.

Ann Hematol. 2016 Jan;95(2):271-8. doi: 10.1007/s00277-015-2537-2. Epub 2015 Oct 30.

PMID:
26518211
10.

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.

Butrym A, Łacina P, Rybka J, Chaszczewska-Markowska M, Mazur G, Bogunia-Kubik K.

Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):151-156. doi: 10.1007/s00005-016-0442-6. Epub 2017 Jan 12.

11.

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.

Qian X, Dimopoulos MA, Amatangelo M, Bjorklund C, Towfic F, Flynt E, Weisel KC, Ocio EM, Yu X, Peluso T, Sternas L, Zaki M, Moreau P, Thakurta A.

Leuk Lymphoma. 2019 Feb;60(2):462-470. doi: 10.1080/10428194.2018.1485915. Epub 2018 Aug 2.

PMID:
30068263
12.

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.

Heintel D, Rocci A, Ludwig H, Bolomsky A, Caltagirone S, Schreder M, Pfeifer S, Gisslinger H, Zojer N, Jäger U, Palumbo A.

Br J Haematol. 2013 Jun;161(5):695-700. doi: 10.1111/bjh.12338. Epub 2013 Apr 9.

PMID:
23565715
13.

[Clinical study of multiple myeloma: a report of 182 cases].

Xu L, Wang Y, Wu W, Yan H, Gao XD, Yu Q, Shen ZX, Mi JQ.

Zhonghua Yi Xue Za Zhi. 2010 Apr 13;90(14):972-7. Chinese.

PMID:
20646647
14.

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.

Jonasova A, Bokorova R, Polak J, Vostry M, Kostecka A, Hajkova H, Neuwirtova R, Siskova M, Sponerova D, Cermak J, Mikulenkova D, Cervinek L, Brezinova J, Michalova K, Fuchs O.

Eur J Haematol. 2015 Jul;95(1):27-34. doi: 10.1111/ejh.12457. Epub 2014 Oct 31.

PMID:
25284710
15.

Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.

Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA.

Clin Cancer Res. 2013 Nov 1;19(21):6030-8. doi: 10.1158/1078-0432.CCR-12-3211. Epub 2013 Aug 30.

16.

Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.

Kasamatsu T, Saitoh T, Ino R, Gotoh N, Mitsui T, Shimizu H, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Murakami H.

Hematol Oncol. 2017 Dec;35(4):711-718. doi: 10.1002/hon.2322. Epub 2016 Jul 13.

PMID:
27405747
17.

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H, Sonneveld P; Dutch-Belgian HOVON group; German GMMG Group.

Blood. 2013 Jan 24;121(4):624-7. doi: 10.1182/blood-2012-06-438101. Epub 2012 Dec 11.

18.

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.

Mlak R, Krawczyk P, Ciesielka M, Kozioł P, Homa I, Powrózek T, Prendecka M, Milanowski J, Małecka-Massalska T.

Clin Transl Oncol. 2016 Sep;18(9):915-24. doi: 10.1007/s12094-015-1461-1. Epub 2015 Dec 9.

19.

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R.

Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3. Erratum in: Leukemia. 2012 Nov;26(11):2445.

20.

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.

Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party (KMMWP).

Ann Hematol. 2010 May;89(5):475-82. doi: 10.1007/s00277-009-0856-x. Epub 2009 Nov 18.

PMID:
19921192

Supplemental Content

Support Center